New City

Alopecia areata AA is a condition where the immune system attacks hair follicles, causing hair loss mainly on the head and face but possibly on other body parts. This research evaluates the safety, effectiveness, and tolerance of upadacitinib, an approved drug, in adolescents and adults with severe AA. The study is a Phase 3 randomized, placebo-controlled, double-blind trial enrolling about 1500 participants worldwide. Participants are randomly assigned to one of three groups receiving different treatments two doses of upadacitinib or placebo. In initial periods, some may switch from placebo to upadacitinib based on their Severity of Alopecia Tool SALT score. Those completing early parts may enter an extension phase receiving upadacitinib for up to 108 weeks. Treatment involves taking oral tablets once daily for up to 160 weeks, with possible re-randomization at Weeks 24 and 52. Throughout the study, participants attend regular clinic visits for medical assessments, blood tests, side effect monitoring, and questionnaires to track treatment effects. Researchers measure hair loss improvement using SALT scores and record adverse events over approximately 164 weeks. Participants are followed for up to 30 days after their last dose for safety monitoring.

Researchers are evaluating the long-term safety of Deucravacitinib compared to Ustekinumab in adults with moderate-to-severe plaque psoriasis. This Phase 3b4 study focuses on cardiovascular events and other health outcomes over an extended period, aiming to understand how these treatments impact patients with psoriasis who have cardiovascular risk factors. The study is led by Bristol-Myers Squibb and involves random assignment of participants to either treatment. Participants receive either Deucravacitinib or Ustekinumab at specified doses on scheduled days. The study is open-label, meaning both participants and researchers know which treatment is being given. This trial runs for up to 5 years, during which patients are monitored for cardiovascular safety and other health events related to their psoriasis treatment. Throughout the study, participants undergo regular assessments to track major cardiovascular events like heart attacks, strokes, and hospitalizations, as well as monitoring for infections, cancer, and treatment side effects. Researchers collect data on liver function and lipid levels up to 60 days after the last dose. The long-term follow-up helps evaluate safety and health outcomes over several years, with study activities continuing until early 2031.

Lichen planopilaris LPP is a type of scarring hair loss caused by inflammation, leading to permanent hair loss and uncomfortable scalp symptoms like itching and burning. Current treatments often dont work well and can have side effects, so new targeted options are needed. Nemolizumab, a drug that blocks the IL-31 receptor and is approved for other itchy skin conditions, is being studied as a potential treatment for LPP in this phase 4 pilot study. Participants in the study will receive nemolizumab through subcutaneous injections every 4 weeks, with doses adjusted based on weight. This is a noncontrolled study, meaning all participants receive nemolizumab without comparison to a placebo or other treatment. The study will last at least 24 weeks, during which participants will be monitored for changes in their LPP symptoms. During the study, participants will have their hair loss and scalp condition assessed using specific scoring systems, including the Lichen Planopilaris Activity Index and the Investigator Global Assessment for scarring alopecia. They will also report on scalp itching using a numerical rating scale. Optional scalp biopsies may be performed for research. Safety and treatment effects will be followed over the 24-week period, with all assessments designed to understand how nemolizumab influences LPP activity and symptoms.

Warts on the hands are common, non-cancerous skin growths caused by the human papillomavirus HPV. Treating warts in children can be difficult because common treatments like cryotherapy and injections are often not well tolerated. Existing creams have limited success and require long use. Researchers are studying tirbanibulin ointment as a possible effective and better-tolerated treatment for hand warts in children aged 8 to 18 years. Participants will apply tirbanibulin ointment 1% to the affected areas on their hands themselves. This study is open-label and involves one treatment group using only this topical medication. Treatment cycles will last up to four cycles, with participants applying the ointment as directed during the study period. During the study, children will be monitored for wart clearance two months after finishing treatment cycles. Assessments will include wart count and size, overall health status, and any side effects. The study will last through treatment and follow-up, ensuring safety and measuring how well the ointment works to clear warts on the hands.